Global Lymphoma Antibodies Market & Clinical Trials Insight 2028

出版日: | 発行: KuicK Research | ページ情報: 英文 3600 Pages | 納期: 即日から翌営業日

価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=128.51円

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

出版日: 2022年05月01日
発行: KuicK Research
ページ情報: 英文 3600 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次





第1章 調査手法

第2章 世界のリンパ腫抗体治療薬市場

  • 現在の市場シナリオ
  • 地域の市場分析
  • 将来の市場機会

第3章 リンパ腫抗体薬物複合体 - 入手可能性、投与量、特許、価格分析

  • ブレンツキシマブベドチン(アドセトリス)
  • ポラツズマブベドチン(ポライビー)
  • ロンカスツキシマブテシリン(ジンロンタ)

第4章 リンパ腫モノクローナル抗体 - 入手可能性、特許、価格、投与量分析

  • ニボルマブ(オプジーボ)
  • タファシタマブ(モンジュビ/ミンジュビ)
  • リツキシマブ(マブセラ/リツキサン)
  • リツキシマブバイオシミラー(トルキシマ)
  • リツキシマブバイオシミラー(リアブニ)
  • リツキシマブバイオシミラー(ルキシエンス)
  • リツキシマブ/ヒアルロニダーゼ(リツキサンハイセラ)
  • オビヌツズマブ(ガザイバ)
  • ペムブロリズマブ(キイトルーダ)
  • シンティリマブ(Tyvyt)
  • カムレリズマブ(AiRuiKa)
  • Tislelizumab(Baize'an)
  • ジンベレリマブ
  • ペンプリマブ

第5章 リンパ腫抗体薬物複合体 - 世界および地域の売上分析

  • アドセトリス
  • ポライビー
  • ジンロンタ

第6章 リンパ腫モノクローナル抗体 - 世界および地域の売上分析

  • オプジーボ
  • モンジュビ
  • リツキサン
  • ガザイバ
  • キイトルーダ

第7章 世界のリンパ腫抗体の臨床試験の概要

  • 企業別
  • 国別
  • フェーズ別
  • 患者セグメント別

第8章 世界のリンパ腫抗体の臨床試験:企業、適応症、フェーズ別

  • 調査
  • 前臨床
  • フェーズ-I
  • フェーズ-I/II
  • フェーズ-II
  • フェーズ-II/III
  • フェーズ-III
  • 事前登録
  • 登録済み

第9章 市販のリンパ腫抗体の臨床的考察:企業、国、適応症別

第10章 競合情勢

  • AbbVie
  • ADC Therapeutics
  • BeiGene
  • Bristol Myers Squibb
  • GlaxoSmithKline
  • Innovent
  • Merck
  • Morphosys
  • Ono Pharmaceutical
  • Pfizer
  • Roche
  • Seagen
  • Takeda Pharmaceuticals

"Global Lymphoma Antibodies Market & Clinical Trials Insight 2028" Report Highlights:

  • Global Lymphoma Antibodies Market Opportunity: >USD 6 Billion
  • Global Lymphoma Antibodies Market Insights: Current, Regional & Future Outlook 2028
  • Annual, Quarterly & Regional Sales Insights On Lymphoma Antibodies
  • Lymphoma Antibodies Availability By Dosage, Patent, & Price Analysis
  • Clinical Insight On More Than 160 Lymphoma Antibodies In Trials
  • Lymphoma Antibodies Clinical Trials Insights by Company, Country & Phase
  • Annual, Quarterly & Regional Sales Insights On Lymphoma Antibodies

In last few years, remarkable progress has been made in the field of immunotherapy. Multiple immunotherapeutic approaches based on different targeting mechanism have emerged as standard treatment methodologies for the management of wide range of cancers, including lymphoma. Amid all approaches, antibody based immunotherapy is considered as main component of lymphoma therapy, alongside surgery, radiation, and chemotherapy. This is mainly attributed to several benefits associated with them in terms of specificity, selectivity, and targetability.

To date, several monoclonal antibodies have been approved for the management of lymphoma including Rituximab, Monjuvi, Keytruda, and others which have shown high adoption rates in the market. To further enhance their efficacy, researchers have developed antibody drug conjugates. Currently, three antibody drug conjugates namely Polivy, Adcetris, and Zynlonta have gained approval for the management of lymphoma. Since the entrance of these drugs, these have shown high adoption rates in the global market which has led to further research and development activities in this domain. Presently, more than 200 clinical trials are ongoing in global lymphoma antibody therapeutics market.

The advancement in the field of biotechnology and the robust research and development activities has led to introduction of next generation antibodies which are designed to be more potent and specific than conventional monoclonal antibodies. Although no bispecific antibody has entered the market, but it is suggested that it will hold a significant share in the forthcoming years which can be justified by the large number of ongoing clinical trials in this domain. For instance, Epcoritamab developed by Genmab's proprietary DuoBody technology is an investigational IgG1-bispecific antibody which is present in phase-I/II clinical trial. The preliminary results have demonstrated encouraging response in the management of relapsed/ refractory large B cell lymphoma.

The global lymphoma antibody therapeutics market is highly competitive and consists of several key players including Roche, Pfizer, ADC Therapeutics, Bristol Myers Squibb, and others. The companies have adopted strategic alliances injcluding partnership, collaboration, or joint ventures to maintain their position in the global market. Recently in 2021, Xencor and Janssen Biotech announced an exclusive collaboration and worldwide license agreement to develop and commercialize plamotamab and novel XmAb® B-cell targeting bispecific antibodies which are designed to conditionally activate T cells through the CD28 co-stimulatory receptor. The investigational Plamotamab is a XmAb bispecific antibody which targets CD20 and CD3 simultaneously. The drug is completing a Phase 1 dose-escalation study in patients with CD20-expressing non-Hodgkin lymphoma. Under the terms of the agreement, Janssen will receive worldwide exclusive development and commercialization rights to plamotamab, whether as a monotherapy or in combination regimens.

As per our report findings, the global lymphoma antibody therapeutics market is expected to surpass US$ 6 Billion by 2028. The global lymphoma antibody therapeutics market is set to witness an impressive growth, primarily due to high unmet clinical needs associated with the disease and emerging product launches. The NHL antibody therapeutics market is the major market among global lymphoma therapeutics market. The promising drug pipeline and evolving treatment patterns are the factors that would largely drive the market growth. Rising prevalence of lymphoma, increasing funding from different governments, growing awareness and accelerated approvals offered by the regulatory authorities are the other factors that would propel the market growth.

Lymphoma Antibodies Therapeutics Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger and acquisitions along with trending innovation and business policies are reviewed in the report.

Table of Contents

1. Research Methodology

2. Global Lymphoma Antibody Therapeutics Market

  • 2.1 Current Market Scenario
  • 2.2 Regional Market Analysis
  • 2.3 Future Market Opportunity

3. Lymphoma Antibody Drug Conjugates - Availability, Dosage, Patent, & Price Analysis

  • 3.1 Brentuximab Vedotin (Adcetris)
  • 3.2 Polatuzumab vedotin (Polivy)
  • 3.3 Loncastuximab Tesirine (Zynlonta)

4. Lymphoma Monoclonal Antibodies - Availability, Patent, Price & Dosage Analysis

  • 4.1 Nivolumab (Opdivo)
  • 4.2 Tafasitamab (Monjuvi/Minjuvi)
  • 4.3 Rituximab (Mabthera/Rituxan)
  • 4.4 Rituximab Biosimilar (Truxima)
  • 4.5 Rituximab Biosimilar (Riabni)
  • 4.6 Rituximab Biosimilar (Ruxience)
  • 4.7 Rituximab/Hyaluronidase (Rituxan Hycela)
  • 4.8 Obinutuzumab (Gazyva)
  • 4.9 Pembrolizumab (Keytruda )
  • 4.10 Sintilimab (Tyvyt)
  • 4.11 Camrelizumab (AiRuiKa)
  • 4.12 Tislelizumab (Baize'an)
  • 4.13 Zimberelimab
  • 4.14 Penpulimab

5. Lymphoma Antibody Drug Conjugates - Global & Regional Sales Analysis

  • 5.1 Adcetris
  • 5.2 Polivy
  • 5.3 Zynlonta

6. Lymphoma Monoclonal Antibodies - Global & Regional Sales Analysis

  • 6.1 Opdivo
  • 6.2 Monjuvi
  • 6.3 Rituxan
  • 6.4 Gazvya
  • 6.5 Keytruda

7. Global Lymphoma Antibodies Clinical Trials Overview

  • 7.1 By Company
  • 7.2 By Country
  • 7.3 By Phase
  • 7.4 By Patient Segment

8. Global Lymphoma Antibodies Clinical Trials By Company, Indication & Phase

  • 8.1 Research
  • 8.2 Preclinical
  • 8.3 Phase-I
  • 8.4 Phase-I/II
  • 8.5 Phase-II
  • 8.6 Phase-II/III
  • 8.7 Phase-III
  • 8.8 Preregistration
  • 8.9 Registered

9. Marketed Lymphoma Antibodies Clinical Insight by Company, Country & Indication

10. Competitive Landscape

  • 10.1 AbbVie
  • 10.2 ADC Therapeutics
  • 10.3 BeiGene
  • 10.4 Bristol Myers Squibb
  • 10.5 GlaxoSmithKline
  • 10.6 Innovent
  • 10.7 Merck
  • 10.8 Morphosys
  • 10.9 Ono Pharmaceutical
  • 10.10 Pfizer
  • 10.11 Roche
  • 10.12 Seagen
  • 10.13 Takeda Pharmaceuticals